Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 janv. 2016 01h00 HE | Source: NOVARTIS FINANCE S.A.

Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations

Strong growth (cc) in full year sales, core operating income and core EPS[2] Net sales up 5% (cc) and core operating income up 10% (cc) Core operating income margin up 1.3 percentage points...
17 janv. 2016 16h00 HE | Source: NOVARTIS FINANCE S.A.

Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US

Cosentyx is the first and only interleukin-17A (IL-17A) inhibitor approved for adult patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) FDA approval for Cosentyx is based...
04 nov. 2015 01h00 HE | Source: NOVARTIS FINANCE S.A.

Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors

Nominees for election by shareholders at Annual General Meeting (AGM) in February 2016 Basel, November 4, 2015 - The Novartis Board of Directors announced today, that it is nominating Ms....
27 oct. 2015 02h00 HE | Source: NOVARTIS FINANCE S.A.

Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance

Solid growth (cc[1]) in Q3 sales, core operating income, core EPS for continuing operations[2] Net sales were USD 12.3 billion (-6%, +6% cc) Operating income was USD 2.2 billion (-18%, +2% cc)...
23 oct. 2015 07h25 HE | Source: NOVARTIS FINANCE S.A.

Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis

Cosentyx (secukinumab) is recommended for approval in Europe for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients Cosentyx demonstrated rapid onset of action...
25 sept. 2015 01h15 HE | Source: NOVARTIS FINANCE S.A.

Novartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approval

Positive opinion from EU review body puts Entresto on track to be approved for HFrEF patients across Europe likely by year end Entresto was studied in world's largest heart ...
24 sept. 2015 12h00 HE | Source: NOVARTIS FINANCE S.A.

Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires

New leader to continue to drive long-term innovation in Novartis research in wide range of therapeutic areas Basel, September 24, 2015 - Novartis announced today that Dr. James (Jay) E....
21 juil. 2015 01h00 HE | Source: NOVARTIS FINANCE S.A.

Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches

Sales, core[1] operating income and core EPS grew (cc[1]) for continuing operations[2] in Q2: Net sales amounted to USD 12.7 billion (-5%, +6% cc) Operating income was USD...
07 juil. 2015 16h33 HE | Source: NOVARTIS FINANCE S.A.

Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization

First in the world approval brings hope of longer life and fewer hospitalizations for millions of Americans with heart failure with reduced ejection fraction Entresto is the first and only...
23 avr. 2015 01h00 HE | Source: NOVARTIS FINANCE S.A.

Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolio

Continuing operations[1] saw sales, core[2] operating income and core EPS grow (cc[2]) in Q1 Net sales were USD 11.9 billion (-7%, +3% cc)[2] Operating income was USD 2.8 billion (-1%, +15% cc)...

Page précédente